Roche subsidiary Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million to expand its cancer molecular residual disease (MRD) testing portfolio. The deal adds Saga’s Pathlight tumor-informed MRD platform, which combines whole-genome sequencing with digital PCR to identify and track structural variants. Foundation said it plans to leverage Roche’s Axelios sequencing and Digital LightCycler PCR technologies to enable decentralized MRD testing using Pathlight. Saga’s test is available in the U.S. for breast and colorectal cancer MRD monitoring and is covered by Medicare for recurrence monitoring in early-stage breast cancer. The transaction is expected to close in Q3 and would integrate Pathlight into Foundation Medicine after completion, reinforcing the push to scale ultra-sensitive MRD tools for recurrence surveillance and trial stratification.